US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus LifeSci Biotech Products ETF

109.66

+2.292.13%

Post-market: 109.660.00000.00%16:10 EDT

Volume:13.30K

Turnover:1.44M

Market Cap:120.62M

PE:- -

High:109.83

Open:109.80

Low:107.61

Close:107.37

52wk High:110.05

52wk Low:68.05

Shares:1.10M

Float Shares:1.10M

Volume Ratio:1.49

T/O Rate:1.21%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Alterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference

Citizens biotechnology analyst holds analyst/industry conference call

Ajinomoto Advances Major Share Buyback, Plans Cancellation of Repurchased Stock

Aptabio Therapeutics Plans Seoul NDR to Deepen R&D Dialogue with Institutions

Latigo Biotherapeutics initiated with a Buy at Goldman Sachs

Actinogen Plans Major Share Placement to Bolster Funding Capacity

Chimeric Therapeutics posts deeper loss as IP impairments push it into net liabilities

New Listing Update | Betta Pharma Re-files for Hong Kong IPO, Leveraging a Quad-Driven Model to Build a Fully Integrated Biopharmaceutical Platform

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO

Takeda receives FDA approval of NDA for Mimrylo

PYC Therapeutics Files 2026 Corporate Governance Statement with ASX

Alvotech to present at upcoming investor conferences in September

Biotron Posts Wider Annual Loss but Boosts Asset Backing Amid Material Uncertainty

Roche receives FDA approval for companion diagnostic tests for Ziihera

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

Revolution Medicines announces FDA approval of Rasonque in adults

RegenXBio reshapes board with new independent director

BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA

Terragen Posts Wider Loss as Revenue Falls and Asset Backing Erodes

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/BBP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Products ETF","latestPrice":109.655,"timestamp":1788379200000,"preClose":107.3666,"halted":0,"volume":13298,"hourTrading":{"tag":"盘后","latestPrice":109.655,"preClose":109.655,"latestTime":"16:10 EDT","volume":9,"amount":986.895,"timestamp":1788379804764,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.021313890912071313,"floatShares":1100004,"shares":1100004,"eps":0,"marketStatus":"Closed","change":2.2884,"latestTime":"09-02 16:00:00 EDT","open":109.7996,"high":109.83,"low":107.61,"amount":1442515,"amplitude":0.020677,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788422400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":107.3666,"sharesOutstanding":600004,"nav":107.332,"aum":118065366.59,"bidAskSpread":0.002354,"postHourTrading":{"tag":"盘后","latestPrice":109.655,"preClose":109.655,"latestTime":"16:10 EDT","volume":9,"amount":986.895,"timestamp":1788379804764,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.492681,"impliedVol":0.2323,"impliedVolPercentile":0.5317},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","floatShares":1100004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.492681,"shares":1100004,"dividePrice":0,"high":109.83,"amplitude":0.020677,"preClose":107.3666,"low":107.61,"week52Low":68.046,"pbRate":"--","week52High":110.05,"institutionHeld":0,"latestPrice":109.655,"eps":0,"divideRate":0,"volume":13298,"delay":0,"ttmEps":0,"open":109.7996,"prevYearClose":79.9149,"prevWeekClose":105.9199,"prevMonthClose":106.46,"prevQuarterClose":96.2686,"fiveDayClose":108.6574,"twentyDayClose":96.8774,"sixtyDayClose":84.0972},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664214842","title":"Alterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664214842","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664214842?lang=en_us&edition=fundamental","pubTime":"2026-09-03 07:47","pubTimestamp":1788392845,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics, a clinical-stage biotechnology company developing disease-modify...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-to-spotlight-msa-program-at-cantor-global-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-to-spotlight-msa-program-at-cantor-global-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","RSPH","FWD","BK4539","DARP","BK4137","FHLC","XBI","BBP","HCSG","XLV","JDOC","SYNB","LABU","BK4585","LENZ","IEIH","AGNG","IBB","LU0029874061.USD","XT","BK4007","BK4588","BBC","LNGR","BK4139","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664843934","title":"Citizens biotechnology analyst holds analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2664843934","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664843934?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:45","pubTimestamp":1788367511,"startTime":"0","endTime":"0","summary":"Analysts discuss showcasing Twilio’s (TWLO) SIGNAL highlights on an Analyst/Industry conference call to be held on September 4. Published first on ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citizens-biotechnology-analyst-holds-analyst-industry-conference-call-thefly-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citizens-biotechnology-analyst-holds-analyst-industry-conference-call-thefly-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","LU0738911758.USD","LU0205193047.USD","XT","BBP","LU1668664300.SGD","AGNG","DARP","TWLO","FWD","LU0106261612.USD","SYNB","CFG","JDOC","LU2357305700.SGD","LU1861559042.SGD","RSPH","BK4551","LU1548497426.USD","LU2237438978.USD","BK4588","BK4608","FHLC","IEIH","LU0012050646.USD","IAT","BK4116","BK4528","BK4613","LU0345770993.USD","IBB","CLOU","LNGR","LU0949170772.SGD","LU0345770308.USD","LU1720051108.HKD","BK4211","LU0661504455.SGD","LU0106831901.USD","LU1861558580.USD","LU1720051017.SGD","LU0205194284.USD","BK4585","LU1791807156.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664891664","title":"Ajinomoto Advances Major Share Buyback, Plans Cancellation of Repurchased Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891664","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664891664?lang=en_us&edition=fundamental","pubTime":"2026-09-02 14:53","pubTimestamp":1788331999,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Ajinomoto Co ( ($JP:2802) ). Ajinomoto Co., Inc., a leading Japanese food and biotechnology group listed on the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ajinomoto-advances-major-share-buyback-plans-cancellation-of-repurchased-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ajinomoto-advances-major-share-buyback-plans-cancellation-of-repurchased-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSPH","BK4585","BK4588","XT","LNGR","AGNG","JDOC","BBP","IEIH","DARP","FHLC","SYNB","FWD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664997828","title":"Aptabio Therapeutics Plans Seoul NDR to Deepen R&D Dialogue with Institutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2664997828","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664997828?lang=en_us&edition=fundamental","pubTime":"2026-09-02 14:21","pubTimestamp":1788330080,"startTime":"0","endTime":"0","summary":"Aptabio Therapeutics, Inc. ( ($KR:293780) ) has provided an update. Aptabio Therapeutics, Inc., a biotechnology company focused on research and dev...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aptabio-therapeutics-plans-seoul-ndr-to-deepen-rd-dialogue-with-institutions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aptabio-therapeutics-plans-seoul-ndr-to-deepen-rd-dialogue-with-institutions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4585","FHLC","FWD","BK4588","IEIH","BK4007","JDOC","LNGR","XT","BK4139","AGNG","DARP","RSPH","IBB","BK4539","SYNB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883471","title":"Latigo Biotherapeutics initiated with a Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883471?lang=en_us&edition=fundamental","pubTime":"2026-09-01 16:30","pubTimestamp":1788251407,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $73 price target Latigo is clinical-stage biotechnology com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/latigo-biotherapeutics-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/latigo-biotherapeutics-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU1668664300.SGD","LU2471134523.USD","LU0345770993.USD","IE00B19Z3B42.SGD","JDOC","BK4550","IE0004086264.USD","BK4516","LU0106831901.USD","LU0210536198.USD","LNGR","IE0004091025.USD","IE0002270589.USD","SYNB","AGNG","BK4504","LU1144417596.USD","LTGO","LU1868836914.USD","LU2237443895.HKD","IE00BFXG1179.USD","IBB","IEIH","LU2237443549.SGD","FHLC","BK4127","LU0868494617.USD","LU2237438978.USD","LU1868836757.USD","LU2896262040.SGD","FWD","IE00BSNM7G36.USD","BK4552","LU2237443382.USD","RSPH","LU0251131958.USD","XT","LU2237443622.USD","BK4007","LU0942090050.USD","GSX","LU1894683348.USD","DARP","BBC","LU1868836591.USD","BBP","LU0096364046.USD","LU2471134796.USD","LU1868837136.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881767","title":"Actinogen Plans Major Share Placement to Bolster Funding Capacity","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881767","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881767?lang=en_us&edition=fundamental","pubTime":"2026-09-01 08:46","pubTimestamp":1788223606,"startTime":"0","endTime":"0","summary":"Actinogen Medical ( ($AU:ACW) ) just unveiled an update. Actinogen Medical Limited, an ASX-listed biotechnology company trading under the code ACW,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actinogen-plans-major-share-placement-to-bolster-funding-capacity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actinogen-plans-major-share-placement-to-bolster-funding-capacity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYNB","BK4588","IBB","FHLC","BK4585","JDOC","LNGR","IEIH","XT","AGNG","DARP","FWD","BBP","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663753250","title":"Chimeric Therapeutics posts deeper loss as IP impairments push it into net liabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2663753250","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663753250?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:33","pubTimestamp":1788165205,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics Ltd. ( ($AU:CHM) ) has shared an announcement. Chimeric Therapeutics Limited is a biotechnology company focused on cell-based...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-posts-deeper-loss-as-ip-impairments-push-it-into-net-liabilities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-posts-deeper-loss-as-ip-impairments-push-it-into-net-liabilities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4007","FHLC","AGNG","XT","BK4588","BK4539","JDOC","BK4139","DARP","FWD","BBP","IEIH","LNGR","RSPH","LENZ","SYNB","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148310736","title":"New Listing Update | Betta Pharma Re-files for Hong Kong IPO, Leveraging a Quad-Driven Model to Build a Fully Integrated Biopharmaceutical Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=1148310736","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148310736?lang=en_us&edition=fundamental","pubTime":"2026-08-31 08:30","pubTimestamp":1788136244,"startTime":"0","endTime":"0","summary":"Based on the Hong Kong Stock Exchange disclosure on August 28, Betta Pharmaceuticals Co., Ltd. (300558.SZ) has submitted a listing application for the Main Board, with CITIC Securities acting as its...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","BK0239","IPOS","BBP","03069","HEXmain","IBBQ","300558","BK0060","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663588047","title":"Protagonist announces Takeda received U.S. FDA approval for MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663588047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663588047?lang=en_us&edition=fundamental","pubTime":"2026-08-31 04:35","pubTimestamp":1788122107,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) announced that Takeda (TAK) received U.S. Food and Drug Administration, FDA, approval for MIMRYLO, a subcutaneously...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","RSPH","BK4585","TBXU","TAK","BK4139","SYNB","PINK","GNMX","XLVX","PSCH","IBB","BBP","BK4007","FRTY","TECB","MRNY","MEDI","IEIH","MRNX","LFSC","NVIB","LABU","PTGX","BK4588","IDNA","GDOC","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019703","title":"Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019703","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019703?lang=en_us&edition=fundamental","pubTime":"2026-08-29 08:52","pubTimestamp":1787964735,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Co ( ($JP:4502) ) just unveiled an announcement. Takeda has secured U.S. FDA approval for MIMRYLO (rusfertide), a first-in-cl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IDNA","MRNX","XLVX","TECB","NVIB","LABU","TBXU","FRTY","SYNB","BBP","BMED","PINK","MRNY","BK4588","IEIH","PSCH","MEDI","IYH","RSPH","GNMX","IBB","GDOC","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016033","title":"Takeda receives FDA approval of NDA for Mimrylo","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016033","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663016033?lang=en_us&edition=fundamental","pubTime":"2026-08-29 07:00","pubTimestamp":1787958013,"startTime":"0","endTime":"0","summary":"Takeda (TAK) announced U.S. FDA approval of the New Drug Application for Mimrylo for the treatment of erythrocytosis in adults with polycythemia ve...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEIH","MRNX","IYH","FRTY","GNMX","MRNY","LABU","GDOC","IBB","MEDI","NVIB","PSCH","LFSC","BK4007","BBP","BK4588","BK4585","RSPH","BMED","TECB","TBXU","IDNA","TAK","SYNB","XLVX","PINK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662065799","title":"PYC Therapeutics Files 2026 Corporate Governance Statement with ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2662065799","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662065799?lang=en_us&edition=fundamental","pubTime":"2026-08-28 17:28","pubTimestamp":1787909297,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited ( ($AU:PYC) ) just unveiled an update. PYC Therapeutics Limited is an Australia-listed biotechnology company that disclose...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-files-2026-corporate-governance-statement-with-asx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-files-2026-corporate-governance-statement-with-asx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BBP","BK4585","BK4007","IBB","IEIH","BK4539","BK4139","XT","DARP","FWD","JDOC","FHLC","AGNG","BK4588","SYNB","RSPH","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085616","title":"Alvotech to present at upcoming investor conferences in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085616","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085616?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:00","pubTimestamp":1787832000,"startTime":"0","endTime":"0","summary":"REYKJAVIK, Iceland, Aug.  27, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for pat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/27/3351931/0/en/alvotech-to-present-at-upcoming-investor-conferences-in-september.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALVO","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662872226","title":"Biotron Posts Wider Annual Loss but Boosts Asset Backing Amid Material Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2662872226","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662872226?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:37","pubTimestamp":1787801870,"startTime":"0","endTime":"0","summary":"Biotron ( ($AU:BIT) ) has shared an announcement. Biotron Limited, an ASX-listed Australian biotechnology company, focuses on antiviral drug develo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biotron-posts-wider-annual-loss-but-boosts-asset-backing-amid-material-uncertainty?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biotron-posts-wider-annual-loss-but-boosts-asset-backing-amid-material-uncertainty?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGNG","DARP","IEIH","IBB","LNGR","SYNB","JDOC","XT","FWD","BK4585","FHLC","BBP","RSPH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662874134","title":"Roche receives FDA approval for companion diagnostic tests for Ziihera","url":"https://stock-news.laohu8.com/highlight/detail?id=2662874134","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662874134?lang=en_us&edition=fundamental","pubTime":"2026-08-27 03:00","pubTimestamp":1787770816,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that it has received FDA approval for expanded use of its PATHWAY HER2 and VENTANA HER2 Dual ISH DNA Probe Cocktail tests. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-receives-fda-approval-for-companion-diagnostic-tests-for-ziihera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-receives-fda-approval-for-companion-diagnostic-tests-for-ziihera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANC","MRNX","IEIH","IYH","FRTY","GNMX","MRNY","LABU","RHHBY","GDOC","IBB","MEDI","NVIB","PSCH","LFSC","BK4007","BBP","BK4588","BK4585","RSPH","BMED","TECB","TBXU","IDNA","03165","HRTS","SYNB","XLVX","PINK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797746","title":"Revolution Medicines prices Rasonque at $39,800 for 30-day supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:45","pubTimestamp":1787766320,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) disclosed that following FDA approval of Rasonque for the treatment of adult patients with metastatic pancreatic adenoc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","BMED","BBH","XLVX","GNMX","BK4588","IE00B4R5TH58.HKD","FRTY","IE00BJJMRZ35.SGD","TBXU","LU0109394709.USD","PINK","MEDI","IDNA","SYNB","BBP","IE0009355771.USD","IE00BFTCPJ56.SGD","RVMD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IYH","IE0002141913.USD","LU0320765992.SGD","PTH","IE0009354923.USD","GDOC","BK4139","IBB","LFSC","LABU","TECB","IEIH","MRNY","RSPH","LU0889565916.HKD","BK4585","MRNX","NVIB","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662074659","title":"Revolution Medicines announces FDA approval of Rasonque in adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2662074659","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662074659?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:05","pubTimestamp":1787763925,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration has approved RASONQUE once-daily oral tablets, for the treatment o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LFSC","RSPH","MRNY","IE0009355771.USD","TBXU","PINK","MEDI","IE00B4R5TH58.HKD","TECB","GDOC","GNMX","LU0320765992.SGD","BBH","IE00BFTCPJ56.SGD","BK4588","IEIH","LABU","BK4585","IE0009354923.USD","MRNX","NVIB","BMED","IE00B2B36J28.USD","LU0889565916.HKD","SYNB","CANC","IE00BJJMRZ35.SGD","RVMD","XLVX","IDNA","PSCH","PTH","FRTY","IE0002141913.USD","BK4139","BBP","IBB","IYH","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662313757","title":"RegenXBio reshapes board with new independent director","url":"https://stock-news.laohu8.com/highlight/detail?id=2662313757","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662313757?lang=en_us&edition=fundamental","pubTime":"2026-08-26 05:17","pubTimestamp":1787692674,"startTime":"0","endTime":"0","summary":"RegenXBio ( ($RGNX) ) has provided an announcement. On August 25, 2026, REGENXBIO Inc. appointed biotechnology investor Greg Ciongoli to its Board ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regenxbio-reshapes-board-with-new-independent-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regenxbio-reshapes-board-with-new-independent-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FHLC","FWD","BK4588","JDOC","XT","IEIH","BBP","DARP","SYNB","RSPH","AGNG","BK4585","LNGR","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530687","title":"BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530687?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:45","pubTimestamp":1787669120,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIH...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP","GDOC","IDNA","GNMX","IEIH","MRNY","BK4526","BMED","NVIB","LABU","ONC","XLVX","PINK","MEDI","MRNX","BK4588","BK4585","TBXU","BK4139","FRTY","TECB","IYH","SYNB","LFSC","PSCH","IBB","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662578669","title":"Terragen Posts Wider Loss as Revenue Falls and Asset Backing Erodes","url":"https://stock-news.laohu8.com/highlight/detail?id=2662578669","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662578669?lang=en_us&edition=fundamental","pubTime":"2026-08-25 13:27","pubTimestamp":1787635670,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Terragen Holdings Ltd ( ($AU:TGH) ). Terragen Holdings Limited, an agricultural biotechnology company, develops...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/terragen-posts-wider-loss-as-revenue-falls-and-asset-backing-erodes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/terragen-posts-wider-loss-as-revenue-falls-and-asset-backing-erodes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","RSPH","JDOC","AGNG","BBP","XT","LNGR","IBB","FHLC","IEIH","SYNB","DARP","FWD","BK4588","IVEG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":130,"code":"91000000","status":"200"}]}}